Ying Huang
CEO & CFO
cell therapycorporate financecommercial strategy
Details
- ●Modalities: CAR-T cell therapy, next-gen cell therapies
- ●Therapeutic areas: oncology, hematology
- ●Key targets: BCMA, CD20, DLL3, claudin-18.2, GPC3
- ●Indications: multiple myeloma, diffuse large B-cell lymphoma, small cell lung cancer, gastric cancer
- ●Funding: N/A (public since 2020, Carvykti generating ~$1B+ annual revenue)
Partners & investors
- Public (NASDAQ: LEGN)· Investor
- Johnson & Johnson (commercialization partner)· Investor
- GenScript (parent company)· Investor
Key considerations
- ●AI tools in use: Proprietary CAR construct design platform, Automated cell manufacturing systems
- ●Dual-epitope CAR design for enhanced binding (computational protein engineering)
- ●Manufacturing automation to reduce vein-to-vein time
- ●Global manufacturing expansion (US, Belgium, China)
Pipeline
- Preclinical1
- Phase 12
- Approved1
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Frank Fan
Co-Founder & Chief Scientific Officer
CAR-T engineeringimmunologygene therapy